Novartis AG (NYSE:NVS) announced the results from two Phase 3 studies (SUNSHINE and SUNRISE) of Cosentyx (secukinumab) in moderate-to-severe hidradenitis suppurativa…
Keefe, Bruyette & Woods analyst Sanjay Sakhrani initiates coverage on Marqeta (NASDAQ:MQ) with a Market Perform rating and announces Price Target of $17.